Ryan Fukushima Sells 120,000 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 120,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00. Following the transaction, the chief operating officer now directly owns 1,007,207 shares in the company, valued at approximately $42,816,369.57. The trade was a 10.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Tempus AI Trading Down 2.4 %

NASDAQ TEM opened at $41.00 on Friday. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $79.49. The business’s 50 day moving average price is $52.64. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TEM. First Horizon Advisors Inc. acquired a new stake in Tempus AI during the 3rd quarter worth $30,000. Sandia Investment Management LP purchased a new stake in shares of Tempus AI in the 2nd quarter valued at about $136,000. Vestor Capital LLC acquired a new stake in shares of Tempus AI in the 3rd quarter valued at about $153,000. Stifel Financial Corp purchased a new position in Tempus AI during the 3rd quarter worth approximately $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new position in Tempus AI during the third quarter worth approximately $258,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Piper Sandler restated a “neutral” rating and set a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and upped their price target for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Wolfe Research began coverage on shares of Tempus AI in a report on Friday. They issued an “outperform” rating and a $60.00 price objective on the stock. Bank of America increased their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday. Finally, Loop Capital increased their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.